DYN – Knox Daily

Insiders Updates

Dyne Therapeutics Inc [DYN] Records 200-Day SMA of $25.63

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Dyne Therapeutics

Analysts Viewpoint

BMO Capital Markets initates Dyne Therapeutics Inc (DYN) stock to an Outperform

Dyne Therapeutics Inc’s recent filing unveils that its Chief Commercial Officer Friedl-Naderer Johanna unloaded Company’s shares for reported $1733.0 on

Analysts Viewpoint

Checking in on Dyne Therapeutics Inc (DYN) after recent insiders movement

Dyne Therapeutics Inc’s filing revealed that its Chief Commercial Officer Friedl-Naderer Johanna unloaded Company’s shares for reported $1733.0 on Mar

Stock Earnings

Dyne Therapeutics Inc [DYN] Chief Commercial Officer makes an insider sale of 143 shares worth 1,733.

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its

Stock Earnings

Dyne Therapeutics Inc (DYN) gets rating Initiated from BMO Capital Markets

Dyne Therapeutics Inc’s recently made public that its Chief Commercial Officer Friedl-Naderer Johanna unloaded Company’s shares for reported $1733.0 on

Insiders Updates

Dyne Therapeutics Inc (DYN) Becoming More Attractive for Investors

Dyne Therapeutics Inc’s recent filing unveils that its Chief Commercial Officer Friedl-Naderer Johanna unloaded Company’s shares for reported $1733.0 on

Insiders Updates

Insider Selling: Friedl-Naderer Johanna, Dyne Therapeutics Inc [DYN] Chief Commercial Officer divested 143 shares

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its

Stock Earnings

Insider Friedl-Naderer Johanna sells 143 of Dyne Therapeutics Inc [DYN] Stock

Dyne Therapeutics Inc’s recent filing unveils that its Chief Commercial Officer Friedl-Naderer Johanna unloaded Company’s shares for reported $1733.0 on

Analysts Viewpoint

Dyne Therapeutics Inc [DYN] Chief Commercial Officer makes an insider sale of 143 shares worth 1,733.

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Dyne Therapeutics

Insiders Updates

The Attractiveness of Investing In Dyne Therapeutics Inc (DYN) is Growing

Dyne Therapeutics Inc’s filing revealed that its Chief Commercial Officer Friedl-Naderer Johanna unloaded Company’s shares for reported $1733.0 on Mar

Tag: DYN